Alliqua Continues to Beef Up its Scientific Advisory Board

Alliqua Inc., a biomedical company that develops and manufactures proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation, has appointed Charles J. Wolff, D.P.M., to its scientific advisory board. The board’s goal is to offer scientific perspectives on Alliqua’s hydrogel technology platform, as well as strategize its entry into medical markets, specifically wound care and transdermal drug delivery

Wolff is a graduate of the State University of New York at Albany and the New York College of Podiatric Medicine. He served his residency in the Northern Virginia Podiatric Residency Program of Georgetown University Hospital. He currently serves as the director of the Department of Podiatric Medicine and Surgery at Nyack Hospital in Nyack, N.Y., and staff attending at Good Samaritan Hospital in Suffern, N.Y., Ramapo Valley Surgical Center in Ramsey, N.J., Orange Regional Medical Center in Middletown, N.Y., and Meadowlands Hospital in Secaucus, N.J. Wolff is a fellow of the American College of Foot and Ankle Surgeons, and a member of the American Podiatric Medical Association and the New York State Podiatric Medical Society. He is board certified by the American Board of Podiatric Surgery Reconstructive Rearfoot/Ankle Surgery and holds professional licenses in New York and New Jersey.

“I am very pleased to have the opportunity to work with such a dynamic and innovative company like Alliqua,” Wolff said. “Having evaluated the company’s newly launched SilverSeal silver based hydrogel wound dressing, I am very encouraged by its upside and the potential for further line extensions and improvements. I look forward to contributing to the development of SilverSeal and other Alliqua products.”

The SilverSeal hydrogel dressing is mad from cross-linked polymer based gel that can be molded into sheets. Silver as an antimicrobial agent has been used increasingly in hospital setting because of an upsurge in antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus, known as MRSA.

“Dr. Wolff is a very well-respected practitioner in markets that our products serve,” said Richard Rosenblum, president of Alliqua. “Having him join our scientific advisory board will help us immensely in our commercialization and future development research efforts. He will be an excellent fit for our Board.”

In May, Alliqua asked Michael F. Moore, M.D., onto the board. He is “Recognized as an expert in the field of wound care,” said Rosenblum, who is assembling quite a group of advisors for his company.

Moore is a graduate of Fairfield University and Albany Medical College. He completed his general surgical training and vascular fellowship at the Albany Medical Center Hospitals. Moore pioneered the treatment of wound care in northeastern Pennsylvania establishing the first wound center in 1997 and has practiced in the region since 1983. Presently as the Medical Director of the Wound Institute and Research Center in Dunmore, Pa., he is conducting research involving interactive dressings and dietary supplements. In his role as medical consultant for Noble Biomaterials and RJL Systems, he is the principal investigator involving the development of a physiologic electronic garment with the U.S. Air Force and the development of a hemostatic antimicrobial dressing for the U.S. Army. Moore has been elected to the board of directors of the Fellows of the American College of Certified Wound Specialists and the advisory nutrition board for Abbott Laboratories.

Like Wolff, Moore praised the features of SilverSeal: “Over the past several years, I have had the opportunity to evaluate the company’s SilverSeal hydrogel and believe that it is a ‘best in class’ type product with respect to multiple wound care applications, particularly diabetic ulcers and skin tears.”

Through its wholly owned subsidiary, Alliqua BioMedical Inc., Alliqua intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform of AquaMed Technologies Inc., another Alliqua subsidiary. Alliqua is based in New York, N.Y.